Get the Free Prostate Cancer Patient Guide now with COVID-19 Appendix.


Go here to learn more or to get a mailed copy.


Progress Report: Eleni Efstathiou, MD, Ph.D

Investigator: Eleni Efstathiou, MD, PhD – Assistant Professor, University of Texas, M.D. Anderson Cancer Center Biomarker Driven Application of Therapy Androgens (male hormones such as testosterone) fuel prostate cancer growth and survival. Androgens are synthesized in the testis and adrenal glands. Therapeutic agents that block the production of androgens (androgen. Read More


Progress Report: Scott Dehm, Ph.D

Investigator: Scott Dehm, PhD – Assistant Professor, University of Minnesota Mechanisms of Androgen Receptor (AR) Activation in Prostate Cancer The standard first line treatment strategy for metastatic prostate cancer is androgen (male hormones) deprivation therapy, such as Lupron, which reduces the level of circulating testosterone (type of androgen), or such. Read More


Progress Report: Atish Choudhury, MD, Ph.D

Investigator: Atish Choudhury, MD, PhD – Assistant Professor, Dana-Farber Cancer Institute Molecular Determinants of Hormone Refractory Prostate Cancer Metastatic prostate cancer initially responds to androgen deprivation therapy (ADT; blockade of male hormones such as testosterone) resulting in tumor regression and improved clinical performance. This is because prostate cancer cell growth. Read More


Progress Report: Gerhardt Attard, MD, Ph.D

Investigator: Gerhardt Attard, MD, PhD – Assistant Professor, Institute for Cancer Research, Royal Marsden Hospital, London Predicting Resistance to Abiraterone: Molecular Analysis of CTCs First-line treatment for recurrent prostate cancer involves blockade of male hormone (testosterone; androgen) production in a process known as androgen deprivation therapy (ADT). Androgens are synthesized. Read More


Progress Report: Mohamed Simon Arredouani, Ph.D

Investigator: Mohamed Simon Arredouani, PhD – Assistant Professor, Beth Israel Deaconess Medical Center Advances in Prostate Cancer Immunotherapy The immune system protects humans and other mammals from disease by recognizing foreign invaders such as bacteria and viruses. It is also thought that tumor cells express molecules foreign to the patient. Read More


Progress Report: John Ward, MD

Investigator: John Ward, MD– Assistant Professor, M.D. Anderson Cancer Center, University of Texas Noninvasive Radiofrequency Field for the Targeted Destruction of Prostate Cancer Using Directed Gold Nanoparticles—Activated Gold Particles Could Provide Novel Means of Destroying Tumors Dr. Ward is investigating a new way to kill prostate cancer cells by targeting. Read More


Progress Report: Muneesh Tewari, MD, Ph.D

Investigator: Muneesh Tewari, MD, PhD–Assistant Member, Fred Hutchinson Cancer Research Center, University of Washington Exosomal RNAs as Serum Prostate Cancer Biomarkers—Personalized Treatment and Better Prognostic Indicators May Become Reality Through MicroRNA Tumor Profiling Dr. Tewari and colleagues have discovered that cancer cells shed tiny vesicles from their membrane, much like. Read More


Progress Report: Pier Paolo Pandolfi, MD, Ph.D

Investigator: Pier Paolo Pandolfi, MD, PhD–George C. Reisman Professor of Medicine, Harvard Medical School, Director, Cancer Genetics Program, Associate Director, Cancer Center Beth Israel Deaconess Medical Center Pro-Senescence Therapy for Prostate Cancer The human body has a number of mechanisms in place to protect against cancer growth and survival. One. Read More


Progress Report: David Nanus, MD

Investigator: David Nanus, MD–Professor of Medicine, Professor of Urology, Mark W. Pasmantier Professor of Hematology and Oncology in Medicine at Weill Cornell Medical College Circulating Tumor Cell Biomarker Discovery of Taxotere Response Docetaxel (Taxotere) chemotherapy is the standard first line treatment for patients with castrate resistant prostate cancer (CRPC). Data. Read More


Progress Report: Towia Libermann, Ph.D; Alan Rigby, Ph.D

Co-Investigator: Towia Libermann, PhD–Associate Professor, Medicine, Director, Genomics and Proteomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Director, Dana Farber Cancer Institute Cancer Proteomics Core, Harvard Medical School Co-Investigator: Alan Rigby, PhD–Assistant Professor, Medicine, Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center, Harvard Medical. Read More